What Merck & Co., Inc. reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 310158 · Filed Aug 7, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 2.3M |
| ±0% |
| $161.6M |
| 30.7% |
KYMRKymera Therapeutics, Inc. | 772.2K | ±0% | $88.5M | 16.8% |
AKTSAktis Oncology, Inc. | 952.8K | ±0% | $30.7M | 5.8% |
EIKNEikon Therapeutics, Inc. | 1.7M | ±0% | $21.7M | 4.1% |
TRDAEntrada Therapeutics, Inc. | 1.7M | New | $12.8M | 2.4% |
STROSutro Biopharma, Inc. | 272.4K | New | $9M | 1.7% |
ALECAlector, Inc. | 3.5M | ±0% | $7.1M | 1.4% |
EVAXEvaxion A/S | 1.2M | New | $3.8M | 0.7% |
VRDNViridian Therapeutics, Inc. | 93.4K | ±0% | $1.7M | 0.3% |
XLOXilio Therapeutics, Inc. | 106K | ±0% | $1M | 0.2% |
HURATuHURA Biosciences, Inc. | 19.4K | ±0% | $45.5K | 0.1% |
NEUPNeuphoria Therapeutics Inc. | 10K | ±0% | $43.8K | 0.1% |
